Modus Therapeutics completes directed issue raising MSEK 7.6
KDventures AB says its portfolio company Modus Therapeutics carried out a directed issue of MSEK 7.6. Net proceeds will finance the 2027 development plan for sevuparin.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.